Christopher A. Evans
GlaxoSmithKline, King of Prussia, PA
Traditionally, plasma is the preferred matrix for performing quantitative bioanalysis of xenobiotics from in vivo evaluations. A novel approach is evolving which employs sampling from dried blood spots (DBS) on specialty papers, rather than conventional plasma analysis. The use of DBS is an established technique for screening newborns for in-born errors of metabolism and for therapeutic drug monitoring. Therefore their use as a replacement matrix to plasma for supporting drug development in preclinical/clinical pharmacokinetic and toxicokinetic studies is under investigation by numerous groups.
The most notable advantage of this technique is the reduced blood collection volume requirements – amenable to both pediatric studies and reduced rodent animal consumption. Additionally, the technique requires less invasive sampling and facilitates easy storage and shipment conditions, with no requirement for freezers and dry ice. For these reasons, this methodology may serve to replace conventional plasma analysis for pharmaceutical development in certain instances. GlaxoSmithKline has adopted DBS as the preferred matrix and sampling technique for all new oral development compounds.
This presentation will increase your awareness around DBS sampling, highlight the advantages and considerations for DBS implementation, and finally discuss its potential impact on animal welfare.